

In re: Generic Pharmaceuticals Pricing Antitrust Litigation
Settlement Administrator
P.O. Box 2750
Portland, OR 97208-2750

Court-Approved Legal Notice

*In re: Generic Pharmaceuticals
Pricing Antitrust Litigation,
Case No. 16-md-2724*

United States District Court for the
Eastern District of Pennsylvania

**If you are a dispenser of drugs
in the U.S. that purchased one
or more “Drugs at Issue” from
January 1, 2010, through
March 5, 2024, a class action
settlement may affect your rights.**

*A Court has authorized this notice.
This is **not** a solicitation from a lawyer.*

GenericPharmaceuticalsAntitrust.com
1-877-644-0182

A \$1 million Settlement has been reached in a class action antitrust lawsuit between Indirect Reseller Plaintiffs and Defendant Breckenridge Pharmaceutical, Inc. (“Breckenridge”). The Settlement only applies to Breckenridge, with the lawsuit continuing against other Defendants. The lawsuit is called *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 16-md-2724 (E.D. Pa.). The Settlement will resolve legal claims that Breckenridge participated in one or more unlawful conspiracies to raise, fix, maintain, and/or stabilize prices, rig bids, and allocate markets and customers for “Drugs at Issue” in violation of Section 1 of the Sherman Act and various state antitrust, unfair competition, unjust enrichment, and consumer protection laws. The “Drugs at Issue” are listed at GenericPharmaceuticalsAntitrust.com. Recently, notice was provided regarding a settlement with Defendant Apotex Corp. and affiliated entities. This Notice is for the Breckenridge Settlement, a new settlement within the same lawsuit.

Who is Included? Records show you are a member of the Settlement Class defined as all dispensers of drugs (including hospitals and independent pharmacies) in the United States and its territories that purchased one or more of the Drugs at Issue directly from distributor AmerisourceBergen Corp., Cardinal, Red Oak, Harvard, H.D. Smith, McKesson, Morris & Dickson, or WBAD or their subsidiaries; and all dispensers of drugs (including hospitals and independent pharmacies) in the State Damages Jurisdictions that purchased one or more of the Drugs at Issue from any source other than the manufacturer Defendants from January 1, 2010, through March 5, 2024. The “State Damages Jurisdictions” are listed at GenericPharmaceuticalsAntitrust.com.

What does the Settlement Provide? If the Settlement is approved, Breckenridge is required to pay \$1,000,000 to resolve all Settlement Class Members’ legal claims against Breckenridge for the Released Claims (as defined in the Settlement Agreement). Breckenridge has also agreed to provide specified cooperation in the Indirect Reseller Plaintiffs’ continued prosecution of the lawsuit.

To receive Settlement benefits, you must submit a timely and valid Claim Form online or by mail. Claim Forms may be submitted until 90 days following the Court’s final approval of the Settlement Agreement. Claim Forms are available at GenericPharmaceuticalsAntitrust.com or by calling 1-877-644-0182.

Other Options. If you do not want to be legally bound by the Settlement, you must opt out of the Settlement no later than **August 6, 2026**. If you do not opt out, you will give up the right to sue and will release the Defendant and Released Parties about any legal claims in this lawsuit. If you do not opt out, you may object to the Settlement by **August 6, 2026**. The Long-Form Notice on the Settlement Website has instructions on how to opt out or object. If you do nothing, you will not get Settlement benefits, and you will be bound by the Settlement and any judgments and orders. The Court will hold a Final Approval Hearing on **November 17, 2026**, to consider whether to approve the Settlement, Class Counsel’s attorneys’ fees request of up to \$333,333 of the \$1 million Settlement Fund, as well as any objections to the Settlement. You or your personal lawyer may attend and ask to appear at the hearing, but you are not required to do so. The hearing may be held remotely, and if so, instructions will be at GenericPharmaceuticalsAntitrust.com.

This notice is a summary. Learn more about the Settlement at GenericPharmaceuticalsAntitrust.com, or by calling toll-free 1-877-644-0182.